Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.
Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.
Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.
John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.
